OpenEvidence, a tool that doctors and nurses have likened to ChatGPT for medicine, plans to announce a $200 million raise at a $6 billion valuation, The New York Times reports.
The fresh funds come three months after the startup raised a $210 million round at a $3.5 billion valuation, a testament to the intense investor interest in industry-specific AI applications.
Trained on medical journals like JAMA and the New England Journal of Medicine, the OpenEvidence platform helps users quickly get answers to existing medical knowledge to help treat patients. Verified medical professionals can access OpenEvidence’s tool, which is supported by advertising, for free.
OpenEvidence has grown quickly since its founding in 2022. Its number of clinical consultations per month has nearly doubled to 15 million since July, per the Times.
The round was led by Google Ventures, with participation from Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft.
TechCrunch has reached out to OpenEvidence for comment.
